(Q34353349)

1 August 2017

1 reference

title

The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure (English)

1 reference

1 August 2017

0 references

1 reference

chronic heart failure

1 reference

D J van Veldhuisen

1

1 reference

1 August 2017

P A Poole-Wilson

series ordinal

2

1 reference

1 August 2017

publication date

1 August 2001

1 reference

International Journal of Cardiology

1 August 2017

published in

1 reference

1 August 2017

volume

80

1 reference

1 August 2017

issue

1

1 reference

1 August 2017

page(s)

19-27

1 reference

The effect of digoxin on mortality and morbidity in patients with heart failure

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

15 years of heart-failure trials: what have we learned?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Mechanisms of positive inotropic action of flosequinan, hydralazine, and milrinone on mammalian myocardium

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Importance of assessing changes in ventricular response to atrial fibrillation during evaluation of new heart failure therapies: experience from trials of flosequinan

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Use of the living with heart failure questionnaire to ascertain patients' perspectives on improvement in quality of life versus risk of drug-induced death

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Endothelin-1 in heart failure: a new therapeutic target?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Heart Failure 99 -- the MOXCON story

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Acute hemodynamic and neurohumoral effects of moxonidine in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure. Moxonidine Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Selective imidazoline receptor agonists for metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: the MACH-1 study. Mortality Assessment in Congestive Heart Failure Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

What lessons can be learnt from withdrawal of mibefradil from the market?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Good news for experimental concept but bad news for clinically effective therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Mibefradil- and ω-conotoxin GVIA-induced inhibition of noradrenaline release from the sympathetic nerves of the human heart

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Effect of mibefradil on heart rate variability in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Immunomodulation: a new horizon for medical treatment of heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Prolongation of murine cardiac allograft survival with vesnarinone

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Dopaminergic drugs in the management of chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Selective and nonselective dopamine receptor agonists: an innovative approach to cardiovascular disease treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Treating chronic heart failure: time to take stock

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Dose-dependent separation of dopaminergic and adrenergic effects of epinine in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Effect of epinine on tension of human renal arteries

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Comparative efficacy of a DA2/alpha2 agonist and a beta-blocker in reducing adrenergic drive and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Direct vasodilating effects of the new dopaminergic agonist Z1046 in human arteries.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Neuroendocrine changes post myocardial infarction: Effects of xamoterol

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

The effects of the partial beta 1-agonist xamoterol on heart rate and ventricular arrhythmias in patients with mild to moderate heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Effects of beta receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: double blind comparison of metoprolol and xamoterol

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Xamoterol in severe heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Hemodynamic effects of the beta 1-adrenoceptor partial agonist xamoterol in relation to plasma norepinephrine levels during exercise in patients with left ventricular dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

The xamoterol experience in the treatment of heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Incidence and aetiology of heart failure; a population-based study.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

A national survey of heart failure in French hospitals. The Myocardiopathy and Heart Failure Working Group of the French Society of Cardiology, the National College of General Hospital Cardiologists and the French Geriatrics Society

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

The agonising negative trend in monitoring of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Clinical trial safety committees: the devil's spoon

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Beta-adrenergic blockers and survival in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Carvedilol in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Molecular basis of cardiovascular drug metabolism: implications for predicting clinically important drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

All that glitters is not gold

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

Academia and industry: increasingly uneasy bedfellows

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900447-8

7 January 2021

10.1016/S0167-5273(01)00447-8

Identifiers

DOI

1 reference

1 August 2017

1 reference